When buying CJC-1295 with DAC for laboratory research, securing analytical-grade material with verified purity and precise structural identity is paramount. CJC-1295 with DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered with a Drug Affinity Complex (DAC) to extend terminal plasma half-life through covalent albumin binding. PX1 Research supplies USA-manufactured CJC-1295 with DAC, accompanied by independent third-party COAs, mass spectrometry identification, HPLC purity analysis, and endotoxin testing for rigorous preclinical inquiry.
When buying CJC-1295 with DAC for laboratory research, securing analytical-grade material with verified purity and precise structural identity is paramount. CJC-1295 with DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered with a Drug Affinity Complex (DAC) to extend terminal plasma half-life through covalent albumin binding. PX1 Research supplies USA-manufactured CJC-1295 with DAC, accompanied by independent third-party COAs, mass spectrometry identification, HPLC purity analysis, and endotoxin testing for rigorous preclinical inquiry.
CJC-1295 with DAC (Drug Affinity Complex) is a modified 29-amino-acid peptide analog of human growth-hormone-releasing hormone (GHRH 1-29). The inclusion of four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) enhances resistance to enzymatic cleavage relative to native GHRH. Coupled to the C-terminus of this tetrasubstituted peptide chain is a reactive maleimidopropionic acid linker, designated as the Drug Affinity Complex.
In biochemical research, CJC-1295 with DAC is categorized among long-acting growth hormone secretagogues. Its chemical structure permits specific bioconjugation with circulating serum albumin post-administration in preclinical animal models. Researchers investigating anterior pituitary somatotrope dynamics rely on CJC-1295 with DAC to evaluate sustained activation of the GHRH receptor axis without the requirement for continuous infusion systems.
Unmodified native GHRH and short-chain analogs exhibit extremely rapid clearance in vivo, primarily driven by dipeptidyl peptidase IV (DPP-IV) enzymatic cleavage between the Tyr1 and Ala2 residues, as well as renal elimination. This rapid degradation yields an elimination half-life of only several minutes in mammalian models.
The integration of the Drug Affinity Complex fundamentally alters these pharmacokinetic parameters. Upon introduction to biological matrixes containing serum albumin, the maleimide functional group on the DAC moiety selectively forms a stable covalent thioether bond with the free Cys34 thiol residue of albumin. Because endogenous serum albumin possesses a protracted systemic circulation half-life, the resulting CJC-1295-albumin conjugate is protected from DPP-IV degradation and renal filtration. This bioconjugation extends the functional half-life of the peptide to several days in rodent and primate models, establishing a sustained baseline exposure.
CJC-1295 with DAC operates as a selective agonist at the growth-hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor located on the plasma membrane of somatotropic cells within the anterior pituitary gland. Upon ligand binding, the receptor undergoes a conformational change that triggers the activation of intracellular heterotrimeric G-protein subunits.
This receptor engagement initiates a downstream signal transduction cascade: stimulation of membrane-bound adenylyl cyclase increases intracellular cyclic adenosine monophosphate (cAMP) concentrations, activating protein kinase A (PKA). PKA subsequently phosphorylates key transcription factors, prompting gene transcription for growth hormone (GH) synthesis and exocytosis. When utilizing CJC-1295 with DAC in vitro or in vivo, researchers observe continuous, non-pulsatile activation of this cascade, leading to sustained transcription and release of GH into circulation.
Literature evaluating CJC-1295 with DAC highlights its capacity to sustain elevated systemic levels of both growth hormone and downstream insulin-like growth factor 1 (IGF-1). Unlike short-acting secretagogues that induce acute, transient GH spikes, CJC-1295 with DAC maintains elevated trough concentrations of IGF-1 over extended observation windows in rodent assays.
Studies investigating preclinical tissue repair mechanisms utilize this sustained IGF-1 elevation to measure rate changes in cellular proliferation, collagen cross-linking, and nitrogen retention in damaged musculoskeletal tissues. Preclinical models demonstrate that continuous signaling through the GH/IGF-1 axis enhances hepatic IGF-1 expression, upregulates protein translation pathways via mTOR, and supports cellular turnover in extracellular matrix models.
Researchers evaluating secretagogue pharmacokinetics often compare CJC-1295 with DAC to alternative GHRH analogs and growth hormone-releasing peptides (GHRPs). The primary differentiator remains the duration of receptor occupancy and systemic half-life.
While CJC-1295 without DAC (frequently referred to as Modified GRF 1-29) shares the identical tetrasubstituted 29-amino-acid backbone, it lacks the maleimide linker. Consequently, Modified GRF 1-29 exhibits a short plasma half-life (approximately 30 minutes) and yields sharp, transient GH pulses. Conversely, CJC-1295 with DAC maintains elevated baseline GH and IGF-1 levels over days. When researchers desire synergistic activation of both GHRHR and the ghrelin receptor (GHS-R1a), CJC-1295 with DAC is occasionally evaluated alongside selective ghrelin mimetics such as Ipamorelin or GHRP-6, which act via independent signal pathways to amplify total pituitary hormone output.
To ensure experimental validity, researchers must verify that purchased peptides strictly adhere to chemical identity and purity specifications. Synthetic peptide synthesis can yield truncation sequences, deletion peptides, or residual chemical impurities if coupling reactions and cleavage steps are not rigorously controlled.
PX1 Research enforces stringent quality control measures evaluated through independent, ISO 17025 accredited laboratories. Every lot of CJC-1295 with DAC undergoes complete analytical characterization before release:
• High-Performance Liquid Chromatography (RP-HPLC): Establishes chromatographic purity, verifying that the target peptide content meets or exceeds 98.0%.
• Mass Spectrometry (MS): Confirms exact molecular mass (MW 3647.95 Da) to ensure proper sequence alignment and correct attachment of the DAC moiety.
• Endotoxin Testing (LAL Assay): Quantifies bacterial endotoxin levels to ensure products remain below strict limits (<0.01 EU/mg) required for sensitive cell culture and in vivo animal assays.
Every batch is fully traceable, and lot-specific Certificates of Analysis (COAs) are accessible through the PX1 Research Quality Hub.
Proper handling and storage protocols are essential to prevent physical degradation, hydrolysis, or aggregation of CJC-1295 with DAC prior to experimental procedures. Peptides are supplied in lyophilized (freeze-dried) cake form to preserve chemical stability during transit.
For laboratory reconstitution, researchers typically utilize analytical-grade solvent media such as bacteriostatic water (containing 0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution. Reconstitution should be performed under a laminar flow hood using sterile technique. The solvent should be introduced gently down the inner glass wall of the vial to allow gradual dissolution without vigorous agitation, which can induce shear stress and mechanical denaturation of the peptide chain.
Lyophilized vials should be stored at -20°C for short-term projects or -80°C for long-term storage. Following reconstitution, liquid solutions must be refrigerated at 2°C to 8°C and used within a defined window to maintain structural integrity and prevent enzymatic breakdown.
PX1 Research is dedicated to supporting academic, biotechnology, and institutional laboratories across the United States with high-grade research compounds. All peptides in our catalog are synthesized in domestic, GMP-compliant facilities subject to strict quality management standards.
Orders placed for CJC-1295 with DAC are dispatched directly from our dual distribution hubs located in California and Arizona, facilitating rapid, temperature-controlled delivery (same-day dispatch for orders confirmed Monday through Friday before cut-off times). Principal investigators and procurement officers seeking bulk quantities, custom aliquoting, or institutional invoicing can explore specialized options through our wholesale laboratory account framework.
Explore our complete line of analytical-grade analogs and secretagogues by visiting the full PX1 research peptide catalog.
What is the key molecular structural difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC contains a C-terminal maleimidopropionic acid linker (the Drug Affinity Complex) attached to a tetrasubstituted 29-amino-acid GHRH analog. CJC-1295 without DAC (Modified GRF 1-29) possesses the identical 29-amino-acid sequence but lacks the maleimide linker, resulting in a substantially shorter biological half-life.
How does the Drug Affinity Complex extend the clearance rate of CJC-1295?
The DAC moiety contains a reactive maleimide functional group that forms a covalent thioether bond with the free Cys34 residue of endogenous serum albumin. By anchoring to circulating albumin, the peptide is shielded from rapid dipeptidyl peptidase IV (DPP-IV) cleavage and renal elimination.
What purity levels are documented on PX1 Research COAs for CJC-1295 with DAC?
PX1 Research requires all CJC-1295 with DAC lots to demonstrate ≥98.0% purity as measured by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), with molecular identity verified by Mass Spectrometry (MS).
Why is endotoxin testing critical for CJC-1295 with DAC in research environments?
Bacterial endotoxins (lipopolysaccharides) can alter cell culture viability, trigger non-specific inflammatory responses in animal models, and compromise experimental reproducibility. PX1 Research tests every batch using chromogenic LAL assays to verify endotoxin levels remain below 0.01 EU/mg.
What diluent is standard for reconstituting CJC-1295 with DAC in laboratory protocols?
Lyophilized CJC-1295 with DAC is typically reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride, depending on the specific requirements of the downstream in vitro or in vivo analytical assay.
How should reconstituted CJC-1295 with DAC solutions be stored in the lab?
Reconstituted peptide solutions should be stored in sterile, sealed glass vials at 2°C to 8°C (refrigerated) protected from direct light exposure. For long-term preservation prior to reconstitution, lyophilized vials should be maintained at -20°C or -80°C.
What primary downstream biomarker is measured in CJC-1295 with DAC research?
Preclinical studies primarily measure circulating serum levels of growth hormone (GH) and hepatic insulin-like growth factor 1 (IGF-1), alongside markers of cellular protein synthesis and nitrogen retention.
Where is PX1 Research CJC-1295 with DAC manufactured and shipped from?
PX1 Research CJC-1295 with DAC is manufactured in USA-based GMP-compliant facilities and shipped directly from state-of-the-art fulfillment centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.